Janux Therapeutics, Inc. (JANX) Return on equity 2021–2025
Janux Therapeutics, Inc. (JANX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-11.9%FY2025 · since FY2021: -8.9% → -11.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -11.9% | -5.1 pp |
| FY2024 | -6.7% | +10.2 pp |
| FY2023 | -16.9% | +2.7 pp |
| FY2022 | -19.7% | -10.7 pp |
| FY2021 | -8.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More JANX financial trends
JANX RevenueJANX Net incomeJANX Net marginJANX Gross profitJANX Gross marginJANX Operating incomeJANX Operating marginJANX Operating cash flowJANX Free cash flowJANX Capital expendituresJANX Stock buybacksJANX Dividends paidJANX Total assetsJANX Total liabilitiesJANX Shareholders’ equityJANX overview →